NCT06348173Completed
Response and Remission to Treatment With Anti-IL5/IL5R Antagonists
Response and Remission to Treatment With Anti-IL5/IL5R Antagonists in a Real-world Setting
Source: ClinicalTrials.gov · Last updated 4 Apr 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of this retrospective observational study is to compare the response and remission rate after treatment with IL5/IL5-R antagonists in asthmatics who would and would have not met the inclusion criteria of the original randomized clinical trials. This study will be performed using the charts of the patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 109 (actual)
- First submitted
- 28 Mar 2024
- Start date
- 1 Jun 2023
- Primary completion date
- 30 Nov 2023
- Lead sponsor
- Université de Montréal
- Diseases
- Asthma
- NCT number
- NCT06348173
What you commit to
- Study type: Observational
- Participants enrolled: 109
- From 1 Jun 2023 to the primary completion date, 30 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Patients 18 years and older who were followed at the outpatient asthma clinic of Sacre-Cœur Hospital and have been treated with anti-IL5/il5R between 2016 and 2020.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Du Sacre Coeur de Montreal Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.